broad-bas product geograph strength evid
reiter market outperform rate rais price target
follow releas result first quarter sale
mln y/i organ cc revenu growth y/i place
compani solid foot start year beat consensu mln
model mln adjust ep y/i compar
prior-year period also came street expect despit
greater headwind fx previous expect new price target
appli price-to-earnings multipl previous ep estim
previous repres slight premium group med-tech
peer consist high earn growth profil
believ share continu appreci consid compani
revenu growth opportun featur organ acceler cc
growth manag secular effort improv profit restructur
initi manufactur excel program strong track record
strateg acquir net leverag support anoth scale
transact essenti compani emerg large-cap play better
prospect time recal within last decad
cover name
broad-bas posit result across segment notabl solid
perform intervent cc y/i intervent urolog
cc y/i oem cc y/i busi vascular access grew
cc y/i surgic put cc y/i anesthesia cc y/i
cc y/i saw declin due part time distributor order far
compani geograph breakdown growth led sale asia
cc y/i driven strength korea southeast asia america
cc y/i saw increas within intervent access vascular product
turn compani key financi metric gross margin
roughli flat y/i adjust oper margin slightli y/i
gross margin posit expans due increas urolift sale
volum cost benefit tfx restructur program gain
off-set neg impact fx increment tariff inflat oper
margin neg impact offset would
without fx headwind addit commerci invest relat
urolift manta product manag re-affirmed adjust
gross margin guidanc bp oper margin
expect bp
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
manag reiter full-year guidanc call sale growth y/i
cc impli bln dollar basi adjust ep
y/i top-lin expect includ decreas caus divestitur tfx surgic product
line off-set recent acquisit manta fx headwind
mostli impact first half year adjust ep growth driven oper leverag
acceler sale growth favor mix manufactur cost-reduct initi
compani also provid commerci regulatori clinic updat urolift product use
treat bph manag comment devic sale forc continu make solid progress
head board end expect build
urologist train use product indic signific opportun
penetr ahead plan begin roll-out next gener devic urolift
latter half expect full convers complet regulatori standpoint
compani continu move reimburs process japan expect limit
releas countri sometim mid-to-l potenti meaning revenu ramp
final urolift alreadi boast larg bodi clinic evid public compani
present real-world result patient year aua meet addit three studi
present confer focus symptom sexual function patient
obstruct median lobe examin use urolift patient acut urinari
retent studi impact urolift implant mri read cancer patient
manag reiter guidanc sale growth adjust ep margin follow
figur highlight key guidanc metric along select commentari
figur follow page highlight result rang revenu metric along
select commentari compani recent chang report segment therefor
estim align report result
rang bln expect headwind foreign exchang revenu urolog intervent access asia key contributor growth divestitur surgic product off-set recent acquisit includ mantagross intervent urolog intervent access product mix expect continu benefit manufactur product improv program previous announc restructur programsoper margin ex increas bp rang includ proactiv invest support launch manta precommerci urolift market develop japan expans urolift dtc campaign result higher mix taxabl incom well normal sbc benefitadj gener signific level oper leverag acceler revenu growth favor mix manufactur cost-reduct init teleflex incorpor
 acommentsvascular mlnannual bpsgross bp flat y/i expans increas urolift volum cost benefit off-set fx increment tariff bpsoper bp y/i neg impact seen gross margin well commerci invest urolift mantatax bpsnet bpsadjust cc driven strong growth picc cvc partli off-set time certain distributor cc solid perform broad-bas growth legaci product line intra-aort balloon pump sonsum bone marrow product sale increas extens micro cathet biolog product previous part legaci vascular solut manta began limit market releas cc decreas primarili due time distributor order impact sale laryng mask product repla plan complet bla submiss cc driven sale asia ligat clip surgic instrument rebound cc revenu cc urolift continu strong momentum begin urolift roll-out latter half full convers expect cc led strong perform fiber expect grow upper singl digit cc attribut declin respiratori bladder manag product teleflex incorpor
pure-play med-tech compani transform via merger acquisit number year industri
conglomer foray medic devic industri began late compani began use polym technolog
manufactur intraven cathet tube ultim sold oem grew medic segment late
acquisit rusch pill weck creat medic busi includ dispos
reusabl devic latex cathet endotrach tube laryngoscop face mask tracheotomi tube urolog
gastroenterolog anesthesiolog market well ligat gener surgic devic transform divest
non-med asset make number mostli bolt-on acquisit cap substanti bln purchas
late compani also purchas lma mln vidacar mln
invest thesi valuat subject number risk oper highli competit medic devic market character
price pressur ip disput medic devic highli regul compani fail fda inspect could receiv
warn letter potenti lose abil sell certain product company-specif front reli acquisit bolster
growth profil increas invest guarante acquisit pipelin product accret valu
compani abl execut oper effici program
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign david turkali daniel stauder
jmp secur current make market secur teleflex incorpor
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic may
co
servic
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
